Citius pharmaceuticals, inc. and citius oncology, inc. announce lymphir™ (denileukin diftitox-cxdl) added to national comprehensive cancer network (nccn) clinical practice guidelines in oncology

Cranford, n.j. , sept. 5, 2024 /prnewswire/ -- citius pharmaceuticals, inc. ("citius pharma" or the "company") (nasdaq: ctxr) and citius oncology, inc. ("citius oncology") (nasdaq: ctor), today announced that lymphir™ has been added to the nccn clinical practice guidelines in oncology (nccn guidelines®).
CTXR Ratings Summary
CTXR Quant Ranking